

# Christopher M Jackson

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5247520/publications.pdf>

Version: 2024-02-01

55  
papers

3,539  
citations

361296

20  
h-index

182361

51  
g-index

56  
all docs

56  
docs citations

56  
times ranked

5436  
citing authors

#	ARTICLE	IF	CITATIONS
1	Anti-PD-1 Blockade and Stereotactic Radiation Produce Long-Term Survival in Mice With Intracranial Gliomas. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013, 86, 343-349.	0.4	757
2	Mechanisms of immunotherapy resistance: lessons from glioblastoma. <i>Nature Immunology</i> , 2019, 20, 1100-1109.	7.0	421
3	Combination Therapy with Anti-PD-1, Anti-TIM-3, and Focal Radiation Results in Regression of Murine Gliomas. <i>Clinical Cancer Research</i> , 2017, 23, 124-136.	3.2	345
4	Anti-PD-1 antitumor immunity is enhanced by local and abrogated by systemic chemotherapy in GBM. <i>Science Translational Medicine</i> , 2016, 8, 370ra180.	5.8	243
5	TIGIT and PD-1 dual checkpoint blockade enhances antitumor immunity and survival in GBM. <i>Oncotarget</i> , 2018, 9, e1466769.	2.1	217
6	Focal Radiation Therapy Combined with 4-1BB Activation and CTLA-4 Blockade Yields Long-Term Survival and a Protective Antigen-Specific Memory Response in a Murine Glioma Model. <i>PLoS ONE</i> , 2014, 9, e101764.	1.1	206
7	Lymphocyte Activation Gene 3 (LAG-3) Modulates the Ability of CD4 T-cells to Be Suppressed In Vivo. <i>PLoS ONE</i> , 2014, 9, e109080.	1.1	138
8	Challenges in Immunotherapy Presented by the Glioblastoma Multiforme Microenvironment. <i>Clinical and Developmental Immunology</i> , 2011, 2011, 1-20.	3.3	119
9	STAT3 Activation in Glioblastoma: Biochemical and Therapeutic Implications. <i>Cancers</i> , 2014, 6, 376-395.	1.7	97
10	Immunotherapy for Brain Cancer: Recent Progress and Future Promise. <i>Clinical Cancer Research</i> , 2014, 20, 3651-3659.	3.2	92
11	Combination anti-CXCR4 and anti-PD-1 immunotherapy provides survival benefit in glioblastoma through immune cell modulation of tumor microenvironment. <i>Journal of Neuro-Oncology</i> , 2019, 143, 241-249.	1.4	88
12	Clinical Trials Investigating Immune Checkpoint Blockade in Glioblastoma. <i>Current Treatment Options in Oncology</i> , 2017, 18, 51.	1.3	69
13	Dendritic cell activation enhances anti-PD-1 mediated immunotherapy against glioblastoma. <i>Oncotarget</i> , 2018, 9, 20681-20697.	0.8	63
14	Systemic Tolerance Mediated by Melanoma Brain Tumors Is Reversible by Radiotherapy and Vaccination. <i>Clinical Cancer Research</i> , 2016, 22, 1161-1172.	3.2	57
15	PD-1, PD-L1, PD-L2 expression in the chordoma microenvironment. <i>Journal of Neuro-Oncology</i> , 2015, 121, 251-259.	1.4	56
16	The role of STAT3 activation in modulating the immune microenvironment of GBM. <i>Journal of Neuro-Oncology</i> , 2012, 110, 359-368.	1.4	54
17	Contrasting impact of corticosteroids on anti-PD-1 immunotherapy efficacy for tumor histologies located within or outside the central nervous system. <i>Oncotarget</i> , 2018, 9, e1500108.	2.1	52
18	Trigeminal Neuralgia: Current Approaches and Emerging Interventions. <i>Journal of Pain Research</i> , 2021, Volume 14, 3437-3463.	0.8	35

#	ARTICLE	IF	CITATIONS
19	Vaccine strategies for glioblastoma: progress and future directions. <i>Immunotherapy</i> , 2013, 5, 155-167.	1.0	33
20	The Translational Potential of Microglia and Monocyte-Derived Macrophages in Ischemic Stroke. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	27
21	Potential Role for STAT3 Inhibitors in Glioblastoma. <i>Neurosurgery Clinics of North America</i> , 2012, 23, 379-389.	0.8	25
22	Combination checkpoint therapy with anti-PD-1 and anti-BTLA results in a synergistic therapeutic effect against murine glioblastoma. <i>OncImmunity</i> , 2021, 10, 1956142.	2.1	22
23	Monocyte-based inflammatory indices predict outcomes following aneurysmal subarachnoid hemorrhage. <i>Neurosurgical Review</i> , 2021, 44, 3499-3507.	1.2	22
24	ATRX loss promotes immunosuppressive mechanisms in IDH1 mutant glioma. <i>Neuro-Oncology</i> , 2022, 24, 888-900.	0.6	20
25	Metastatic Melanoma to the Brain: Surgery and Radiation Is Still the Standard of Care. <i>Current Treatment Options in Oncology</i> , 2013, 14, 264-279.	1.3	19
26	A Crowdsourced Consensus on Supratotal Resection Versus Gross Total Resection for Anatomically Distinct Primary Glioblastoma. <i>Neurosurgery</i> , 2021, 89, 712-719.	0.6	19
27	Aneurysm Formation in Proinflammatory, Transgenic Haptoglobin 2-2 Mice. <i>Neurosurgery</i> , 2013, 72, 70-76.	0.6	16
28	Current Trends in Glioblastoma Multiforme Treatment: Radiation Therapy and Immune Checkpoint Inhibitors. <i>Brain Tumor Research and Treatment</i> , 2013, 1, 2.	0.4	15
29	CLEC5A expressed on myeloid cells as a M2 biomarker relates to immunosuppression and decreased survival in patients with glioma. <i>Cancer Gene Therapy</i> , 2020, 27, 669-679.	2.2	15
30	Immunotherapy for Glioblastoma: Playing Chess, Not Checkers. <i>Clinical Cancer Research</i> , 2018, 24, 4059-4061.	3.2	14
31	Application of unruptured aneurysm scoring systems to a cohort of ruptured aneurysms: are we underestimating rupture risk?. <i>Neurosurgical Review</i> , 2021, 44, 3487-3498.	1.2	14
32	Strain-specific induction of experimental autoimmune prostatitis (EAP) in mice. <i>Prostate</i> , 2013, 73, 651-656.	1.2	13
33	The potential for immune checkpoint modulators in cerebrovascular injury and inflammation. <i>Expert Opinion on Therapeutic Targets</i> , 2021, 25, 101-113.	1.5	13
34	Clinical Outcomes after Treatment of Germ Cell Tumors. <i>Neurosurgery Clinics of North America</i> , 2011, 22, 385-394.	0.8	12
35	Absence of Ischemic Injury after Sacrificing the Superior Petrosal Vein during Microvascular Decompression. <i>Operative Neurosurgery</i> , 2020, 18, 316-320.	0.4	12
36	Patient-Specific Factors Drive Intensive Care Unit and Total Hospital Length of Stay in Operative Patients with Brain Tumor. <i>World Neurosurgery</i> , 2021, 153, e338-e348.	0.7	12

#	ARTICLE	IF	CITATIONS
37	Synergy between glutamate modulation and anti- $\alpha$ -programmed cell death protein 1 immunotherapy for glioblastoma. <i>Journal of Neurosurgery</i> , 2022, 136, 379-388.	0.9	11
38	PD-1+ Monocytes Mediate Cerebral Vasospasm Following Subarachnoid Hemorrhage. <i>Neurosurgery</i> , 2021, 88, 855-863.	0.6	11
39	Natural History of Untreated Transverse/Sigmoid Sinus Thrombosis Following Posterior Fossa Surgery: Case Series and Literature Review. <i>Operative Neurosurgery</i> , 2020, 19, 109-116.	0.4	9
40	The Effects of Postoperative Neurological Deficits on Survival in Patients With Single Brain Metastasis. <i>Operative Neurosurgery</i> , 2020, 19, 628-634.	0.4	8
41	Development of new brain metastases in triple negative breast cancer. <i>Journal of Neuro-Oncology</i> , 2021, 152, 333-338.	1.4	8
42	Sustained localized delivery of immunotherapy to lymph nodes reverses immunosuppression and increases long-term survival in murine glioblastoma. <i>Oncolimmunology</i> , 2021, 10, 1940673.	2.1	7
43	The safety and efficacy of dexamethasone in the perioperative management of glioma patients. <i>Journal of Neurosurgery</i> , 2022, 136, 1062-1069.	0.9	7
44	Epidemiology and outcomes of pediatric intracranial aneurysms: comparison with an adult population in a 30-year, prospective database. <i>Journal of Neurosurgery: Pediatrics</i> , 2021, 28, 685-694.	0.8	7
45	Aging Patient Population With Ruptured Aneurysms: Trend Over 28 Years. <i>Neurosurgery</i> , 2021, 88, 658-665.	0.6	7
46	PD-L1, PD-1, LAG-3, and TIM-3 in Melanoma: Expression in Brain Metastases Compared to Corresponding Extracranial Tumors. <i>Cureus</i> , 2019, 11, e6352.	0.2	7
47	Social determinants of health and the prediction of 90-day mortality among brain tumor patients. <i>Journal of Neurosurgery</i> , 2022, 137, 1338-1346.	0.9	6
48	Pediatric glioblastoma: mechanisms of immune evasion and potential therapeutic opportunities. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 1813-1822.	2.0	5
49	Retrosigmoid approach for glycerin rhizotomy in the treatment of trigeminal neuralgia without overt arterial compression: updated case series. <i>Journal of Neurosurgery</i> , 2020, 132, 1227-1233.	0.9	4
50	Novel Predictive Models for High-Value Care Outcomes Following Glioblastoma Resection. <i>World Neurosurgery</i> , 2022, 161, e572-e579.	0.7	4
51	Bone Cement Internal Auditory Canal Reconstruction to Reduce CSF Leak After Vestibular Schwannoma Retrosigmoid Approach. <i>Otology and Neurotology</i> , 2021, 42, e1101-e1105.	0.7	3
52	Predicting High-Value Care Outcomes After Surgery for Non- $\alpha$ -Skull Base Meningiomas. <i>World Neurosurgery</i> , 2022, 159, e130-e138.	0.7	3
53	IMST-58. MODULATING THE MYELOID COMPARTMENT TO POTENTIATE ANTI-PD1 MEDIATED IMMUNOTHERAPY AGAINST GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2016, 18, vi99-vi99.	0.6	0
54	RADI-23. Exploring the optimal timing of routine initial surveillance MRI following treatment of brain metastases with stereotactic radiosurgery: a comparison of two approaches. <i>Neuro-Oncology Advances</i> , 2021, 3, iii23-iii23.	0.4	0

#	ARTICLE	IF	CITATIONS
55	RADI-22. Toxicity and local control outcomes for brain metastases managed with resection and aggressive reirradiation after initial radiosurgery failure. <i>Neuro-Oncology Advances</i> , 2021, 3, iii22-iii23.	0.4	0